×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IOVA – iovance biotherapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IOVA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
02:11 pm
iova
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/9
08:53 am
iova
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
11/8
08:19 am
iova
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... [Yahoo! Finance]
11/7
07:48 pm
iova
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/7
04:18 pm
iova
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 [Yahoo! Finance]
11/7
04:08 pm
iova
Iovance Biotherapeutics GAAP EPS of -$0.28 beats by $0.02, revenue of $58.6M beats by $4.78M [Seeking Alpha]
Low
Report
Iovance Biotherapeutics GAAP EPS of -$0.28 beats by $0.02, revenue of $58.6M beats by $4.78M [Seeking Alpha]
11/7
04:01 pm
iova
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
High
Report
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
11/6
08:07 am
iova
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Low
Report
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/7/2024
04:01 pm
iova
iovance biotherapeutics, inc.
BEAT
Report
-13.8%
iovance biotherapeutics, inc.
8/8/2024
04:01 pm
iova
iovance biotherapeutics, inc.
BEAT
Report
24.9%
iovance biotherapeutics, inc.
5/9/2024
04:01 pm
iova
iovance biotherapeutics, inc.
BEAT
Report
-18.5%
iovance biotherapeutics, inc.
2/28/2024
04:01 pm
iova
iovance biotherapeutics, inc.
MISS
Report
-8.6%
iovance biotherapeutics, inc.
Date
Time
Symbol
Headline
Impact
11/14
05:00 pm
iova
Form 4 IOVANCE BIOTHERAPEUTICS, For: Nov 12 Filed by: Maynard Ryan D
Medium
Report
Form 4 IOVANCE BIOTHERAPEUTICS, For: Nov 12 Filed by: Maynard Ryan D
11/14
04:51 pm
iova
Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: PERCEPTIVE ADVISORS LLC
Medium
Report
Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: PERCEPTIVE ADVISORS LLC
11/12
07:11 pm
iova
Form 144 IOVANCE BIOTHERAPEUTICS, Filed by: Maynard Ryan D
Medium
Report
Form 144 IOVANCE BIOTHERAPEUTICS, Filed by: Maynard Ryan D
11/8
06:04 am
iova
Form 8-K IOVANCE BIOTHERAPEUTICS, For: Nov 07
Medium
Report
Form 8-K IOVANCE BIOTHERAPEUTICS, For: Nov 07
11/7
05:19 pm
iova
Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Sep 30
Low
Report
Form 10-Q IOVANCE BIOTHERAPEUTICS, For: Sep 30
11/7
04:07 pm
iova
Form 8-K IOVANCE BIOTHERAPEUTICS, For: Nov 07
Low
Report
Form 8-K IOVANCE BIOTHERAPEUTICS, For: Nov 07
10/18
08:38 am
iova
Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: STATE STREET CORP
Low
Report
Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: STATE STREET CORP
10/16
06:33 pm
iova
Form 4 IOVANCE BIOTHERAPEUTICS, For: Oct 14 Filed by: Vogt Frederick G
Medium
Report
Form 4 IOVANCE BIOTHERAPEUTICS, For: Oct 14 Filed by: Vogt Frederick G
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/15
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs
36.1%
2/24 Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: Avoro Capital Advisors LLC 27.4%
4/13 Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 17.5%
11/7 Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November 15.8%
3/23 Novan up 27% on favorable safety profile of SB206, Covid-19 plan [Seeking Alpha] 11.6%
2/25 Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.3%
1/8 Iovance Biotherapeutics Inc (NASDAQ: IOVA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.4%
11/4 Q3/2019 9/30/2019 EPS -0.400 ZacksConsensus -0.400 ActVsEst 0.000 - In-Line 6.6%
10/2 Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting 6.9%
6/3 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at HC Wainwright from $26.00 to $32.00. They now have a "buy" rating on the stock. 8.0%
2/24 Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: Avoro Capital Advisors LLC 27.4%
4/13 Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 17.5%
11/7 Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November 15.8%
3/23 Novan up 27% on favorable safety profile of SB206, Covid-19 plan [Seeking Alpha] 11.6%
2/25 Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.3%
1/8 Iovance Biotherapeutics Inc (NASDAQ: IOVA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.4%
11/4 Q3/2019 9/30/2019 EPS -0.400 ZacksConsensus -0.400 ActVsEst 0.000 - In-Line 6.6%
10/2 Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting 6.9%
6/3 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at HC Wainwright from $26.00 to $32.00. They now have a "buy" rating on the stock. 8.0%
TOP News Decliners
11/21
Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy
-4.4%
4/27 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at Chardan Capital from $36.00 to $44.00. They now have a "buy" rating on the stock. -4.5%
8/2 Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.1%
6/11 Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors -5.3%
8/1 Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 01 -6.9%
9/25 Form EFFECT IOVANCE BIOTHERAPEUTICS, -8.1%
4/28 Frazier Healthcare Partners Adds Experienced Capital Markets Executive to Life Sciences Team -10.0%
5/31 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock. -10.9%
1/12 BRIEF-Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog [Reuters] -14.5%
3/16 Iovance Biotherapeutics Inc (NASDAQ: IOVA) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -20.2%
4/27 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at Chardan Capital from $36.00 to $44.00. They now have a "buy" rating on the stock. -4.5%
8/2 Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.1%
6/11 Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors -5.3%
8/1 Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 01 -6.9%
9/25 Form EFFECT IOVANCE BIOTHERAPEUTICS, -8.1%
4/28 Frazier Healthcare Partners Adds Experienced Capital Markets Executive to Life Sciences Team -10.0%
5/31 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock. -10.9%
1/12 BRIEF-Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog [Reuters] -14.5%
3/16 Iovance Biotherapeutics Inc (NASDAQ: IOVA) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -20.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: